Merck & Co hopes for foothold in early TNBC after Keytruda t...

Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall

Tecentriq beats rivals to EU breast cancer market

Study resurrects Merck’s hopes for Keytruda in breast cancer

Merck & Co's Keytruda fails in triple negative breast cancer...

Most of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of cancers – but it has produced an uncharacteristic failure in tough to treat tri

BMS and Infinity aim to overcome triple negative breast canc...

BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy in triple negative breast cancer patients.